Key result
MicroRNA-375 inhibition prevents doxorubicin-induced systolic dysfunction and cardiotoxicity in mice via PDK1/AKT signaling.
Why the study?
MicroRNA-375 expression is increased in heart failure models and its inhibition improves cardiomyocyte survival, but the effects and mechanisms of miR-375 inhibition in doxorubicin-induced cardiac toxicity remained to be investigated.
Does inhibition of microRNA-375 prevent oxidative damage, cardiomyocyte apoptosis, and cardiac dysfunction in preclinical models of doxorubicin-induced cardiac toxicity?
Does inhibition of microRNA-375 prevent oxidative damage, cardiomyocyte apoptosis, and cardiac dysfunction in preclinical models of doxorubicin-induced cardiac toxicity?
Identifies microRNA-375 inhibition as a potential cardioprotective strategy against doxorubicin-induced cardiotoxicity via reactivation of the PDK1/AKT survival pathway.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in mice; leaves open translation of microRNA-375 inhibition to clinical doxorubicin cardiotoxicity.
BACKGROUND Doxorubicin-induced myocardial toxicity is associated with oxidative stress, cardiomyocyte, apoptosis, and loss of contractile function. Previous studies showed that microRNA-375 (miR-375) expression was increased in mouse models of heart failure and clinically, and that inhibition of miR-375 reduced inflammation and increased survival of cardiomyocytes. This study aimed to investigate the effects and mechanisms of inhibition of miR-375 in a mouse model of doxorubicin-induced cardiac toxicity in vivo and in doxorubicin-treated rat and mouse cardiomyocytes in vitro. MATERIAL AND METHODS The mouse model of doxorubicin-induced cardiac toxicity was developed using an intraperitoneal injection of doxorubicin (15 mg/kg diluted in 0.9% saline) for eight days. Treatment was followed by a single subcutaneous injection of miR-375 inhibitor. H9c2 rat cardiac myocytes and adult murine cardiomyocytes (AMCs) were cultured in vitro and treated with doxorubicin, with and without pretreatment with miR-375 inhibitor. RESULTS Doxorubicin significantly upregulated miR-375 expression in vitro and in vivo, and inhibition of miR-375 re-established myocardial redox homeostasis, prevented doxorubicin-induced oxidative stress and cardiomyocyte apoptosis, and activated the PDK1/AKT axis by reducing the direct binding of miR-375 to 3' UTR of the PDK1 gene. Inhibition of PDK1 and AKT abolished the protective role of miR-375 inhibition on doxorubicin-induced oxidative damage. CONCLUSIONS Inhibition of miR-375 prevented oxidative damage in a mouse model of doxorubicin-induced cardiac toxicity in vivo and in doxorubicin-treated rat and mouse cardiomyocytes in vitro through the PDK1/AKT signaling pathway.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2020) studied Doxorubicin-induced cardiac toxicity. Locked nucleic acid (LNA) modified microRNA-375 (miR-375) inhibitor vs. Scrambled oligo control (CTRL) or normal saline was evaluated on Myocardial oxidative damage, cardiomyocyte apoptosis, and cardiac systolic/contractile function (p=<0.05). Inhibition of microRNA-375 prevented doxorubicin-induced myocardial oxidative stress, cardiomyocyte apoptosis, and systolic dysfunction in mice by activating the PDK1/AKT signaling pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: